Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Stock Forecast for 2023 - 2025 - 2030
Updated on 05/16/2024
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Fair Value Forecast for 2023 - 2025 - 2030
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's Price has increased by 100.00% In the last year, going from ¥0.00 to ¥0.00. In the next year, analysts expect Fair Value to reach ¥0.00 – an increase of 100.00%. For the next six years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600276 Stock Forecast | Jiangsu Hengrui Medicine | Buy |
15
|
¥44.69 | Buy/Sell | ¥56.49 | 20.83% |
| T14 Stock Forecast | Tianjin Pharmaceutical Da Ren ... | Outperform |
18
|
$36.46 | Buy/Sell | $1.70 | 25.62% |
| 600436 Stock Forecast | Zhangzhou Pientzehuang Pharmac... | Outperform |
18
|
¥236.94 | Buy/Sell | ¥302.86 | 19.25% |
| 000538 Stock Forecast | Yunnan Baiyao Group Co.,Ltd | Outperform |
18
|
¥55.24 | Buy/Sell | ¥65.39 | 17.38% |
| 1093 Stock Forecast | CSPC Pharmaceutical Group | Buy |
18
|
HK$6.69 | Buy/Sell | HK$9.50 | 39.01% |
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Revenue Forecast for 2023 - 2025 - 2030
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's Revenue has decreased by 47.29% In the last two years, from ¥206.63M to ¥108.91M. In the next year, analysts expect Revenue to reach ¥149.05M – an increase of 36.86%. For the next eight years, the forecast is for Revenue to grow by 44.20%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600085 Stock Forecast | Beijing Tongrentang | Outperform |
16
|
¥46.78 | Buy/Sell | ¥61.18 | 19.71% |
| 000999 Stock Forecast | China Resources Sanjiu Medical... | Buy |
18
|
¥63.55 | Buy/Sell | ¥65.95 | 7.22% |
| 600196 Stock Forecast | Shanghai Fosun Pharmaceutical ... | Outperform |
16
|
¥23.72 | Buy/Sell | ¥33.57 | 10.03% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600079 Stock Forecast | Humanwell Healthcare (Group) | Buy |
0
|
¥20.11 | Buy/Sell | ¥32.49 | -100.00% |
| 000513 Stock Forecast | Livzon Pharmaceutical Group | Outperform |
18
|
¥36.98 | Buy/Sell | ¥39.23 | 11.41% |
| 300146 Stock Forecast | Byhealth | Outperform |
15
|
¥15.74 | Buy/Sell | ¥26.39 | 30.24% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600518 Stock Forecast | Kangmei Pharmaceutical | - |
6
|
¥1.94 | Buy/Sell | ¥25.97 | -100.00% |
| 002262 Stock Forecast | Jiangsu Nhwa Pharmaceutical Co... | Buy |
18
|
¥23.68 | Buy/Sell | ¥31.34 | 30.91% |
| 900904 Stock Forecast | Shanghai Shenqi Pharmaceutical... | - |
13
|
$6.61 | Buy/Sell | $0.00 | -100.00% |
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's EBITDA has grown from ¥-6.45M to ¥-29.02M – a 349.92% increase. For the next year, 0 analysts project Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's EBITDA to drop by 44.07%, reaching ¥-16.23M. By 2030, professionals believe that Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's EBITDA will decrease by 32.65%, reaching ¥-19.54M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600062 Stock Forecast | China Resources Double-Crane P... | Buy |
16
|
¥23.12 | Buy/Sell | ¥26.00 | 11.33% |
| 600380 Stock Forecast | Joincare Pharmaceutical Group ... | Buy |
18
|
¥11.61 | Buy/Sell | ¥14.72 | 26.79% |
| 002773 Stock Forecast | Chengdu Kanghong Pharmaceutica... | Buy |
11
|
¥22.56 | Buy/Sell | ¥24.00 | -100.00% |
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's EBIT has grown by 190.47%, rising from ¥-15.11M to ¥-43.89M. According to 0 prominent analysts, Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's EBIT will fall by 38.41% in the next year, reaching ¥-27.03M. By 2030, professionals believe that Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's EBIT will decrease by 29.97%, reaching ¥-30.74M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600867 Stock Forecast | Tonghua Dongbao Pharmaceutical | Outperform |
18
|
¥10.03 | Buy/Sell | ¥14.25 | 41.77% |
| 603858 Stock Forecast | Shandong Buchang Pharmaceutica... | - |
18
|
¥16.85 | Buy/Sell | ¥0.00 | -100.00% |
| 000623 Stock Forecast | Jilin Aodong Pharmaceutical Gr... | Buy |
16
|
¥15.28 | Buy/Sell | ¥0.00 | 48.36% |
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd EPS Price Prediction Forecast for 2023 - 2025 - 2030
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's EPS has increased by 100.00% In the last year, going from ¥-0.12 to ¥0.00. In the next year, analysts expect EPS to reach ¥0.00 – an increase of 100.00%. For the next six years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600422 Stock Forecast | KPC Pharmaceuticals,Inc | Buy |
18
|
¥22.80 | Buy/Sell | ¥28.00 | 9.69% |
| 000766 Stock Forecast | Tonghua Golden-Horse Pharmaceu... | - |
11
|
¥17.20 | Buy/Sell | ¥33.00 | -100.00% |
| 002019 Stock Forecast | Yifan Pharmaceutical | Buy |
16
|
¥13.73 | Buy/Sell | ¥16.42 | 38.38% |
Site Navigation
.jpg)